Company intelligence / Profile preview

Checkerspot

Ownership: Private
Employees: ~77
Development stage: Commercial

Overview

Checkerspot has achieved commercial-scale production of high-value triglyceride fats and oils using precision fermentation of microalgae. In 2024–2025 it announced breakthroughs including a human breast milk fat analog and the world’s first high oleic palm oil alternative produced entirely via non-GMO microalgae fermentation. Its platform enables distributed manufacturing of sustainable ingredients that replace commodity plant/petroleum-based inputs across multiple industries. The company’s innovations address supply chain resilience, environmental sustainability, and performance needs in consumer products.

Industry: Non-Drug Biotech

Partnerships

Beyond Surface Technologies

Beyond the preview

Go deeper on Checkerspot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Checkerspot.

Explore the full profile